Cargando…
Macitentan treatment of portopulmonary hypertension with hepatopulmonary syndrome: a case report and literature review
Pulmonary arterial hypertension‐targeted therapies in portopulmonary hypertension (PoPH) are scarce, let alone for patients with chronic liver failure (CLF) and hepatopulmonary syndrome (HPS). A 48‐year male was admitted to the hospital because of cirrhosis for 18 years, systemic oedema, and chest d...
Autores principales: | Li, Niuniu, Wu, Qiang, Meng, Juan, Feng, Cheng, Jiang, Siwei, Chen, Meixia, Xu, Wenhui, Wang, Fei, Zhang, Yifan, Liu, Juncai, Xu, Cheng, Liu, Gaolin, Gao, Hong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10375108/ https://www.ncbi.nlm.nih.gov/pubmed/37313579 http://dx.doi.org/10.1002/ehf2.14431 |
Ejemplares similares
-
Transition from Hepatopulmonary Syndrome to Portopulmonary Hypertension: A Case Series of 3 Patients
por: Zopey, Radhika, et al.
Publicado: (2013) -
Aggravation of Hepatopulmonary Syndrome after Sildenafil Treatment in a Patient with Coexisting Portopulmonary Hypertension
por: Chung, Seungmin, et al.
Publicado: (2015) -
Portopulmonary hypertension
por: Saleemi, Sarfraz
Publicado: (2010) -
Macitentan Improves Risk Categorization for Liver Transplant Mortality in Patients With Portopulmonary Hypertension: A PORTICO Study Post Hoc Analysis
por: Krowka, Michael, et al.
Publicado: (2020) -
Portopulmonary Hypertension: An Updated Review
por: Jasso-Baltazar, Erick A., et al.
Publicado: (2023)